Nanobiotix S.A.
NASDAQ:NBTXBiotechnology
-$0.33 today
- Market cap
- $1.37B
- Beta
- 0.59
- P/E (TTM)
- -60.2
- EPS (TTM)
- -$0.51
Volume 0.04M
Average 0.08M
NBTX Total Current Liabilities
All obligations due within one year.
Nanobiotix S.A.NASDAQ: NBTX
Total Current Liabilities · Q4 FY2025 · quarter ended Dec 2025
Total current liabilities falls 2.4% from a year ago
Total current liabilities stood at €57.51M at the end of Q4 FY2025, down 2.4% from a year earlier. Over 3 fiscal years it compounded at +14.9% a year.
Context
- Total current liabilities amounted to 84.9% of total assets at the end of Q4 FY2025, down 2.5 pp from a year earlier.
- Total current liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether total current liabilities keeps falling in the next quarterly balance sheet after a -2.4% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Liabilities history
EUR · from the balance sheet
- Latest · FY2025
- 57.51M EUR
- Year-over-year change
- -2.4%
- 4-year CAGR
- +11.8%
| Period | Period end | Total Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 57.51M | -2.4% |
| FY2024 | 2024-12-31 | 58.94M | +18.2% |
| FY2023 | 2023-12-31 | 49.87M | +31.5% |
| FY2022 | 2022-12-31 | 37.94M | +3.0% |
| FY2021 | 2021-12-31 | 36.85M | — |
Total Current Liabilities vs competitors
How NBTX compares with its peers on the latest reported figures
- Peers report in different currencies, so total current liabilities is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -2.4% is the 7th highest of 11, against a peer median of +13.2%.
- Total current liabilities amounts to 84.9% of total assets for NBTX, versus a peer median of 13.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $101.5M USD | +13.1% | +69.4% | 15.6% | |
| Sep 2026 | $98.09M USD | +71.7% | -50.2% | 16.1% | |
| Mar 2026 | $86.17M USD | -8.9% | +60.5% | 18.2% | |
| Mar 2026 | $59.74M USD | -31.1% | +1.6% | 31.0% | |
| Dec 2025 | €57.51M EUR | -2.4% | +14.9% | 84.9% | |
| Mar 2026 | $25M USD | +93.0% | +45.9% | 7.2% | |
| Mar 2026 | $19.26M USD | +35.2% | +47.0% | 4.7% | |
| Mar 2026 | $14.53M USD | -13.7% | +1.0% | 10.9% | |
| Mar 2026 | $11.18M USD | +21.6% | +29.1% | 44.0% | |
| Mar 2026 | $10.54M USD | +13.2% | +99.5% | 11.0% | |
| Mar 2026 | $7.05M USD | -64.9% | +17.0% | 3.5% | |
| Peer median (excluding NBTX) | — | +13.2% | +37.5% | 13.3% | |
Competitors are the stored peer set for NBTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 83.92M | 41.39M | 75.28M | 49.74M | 52.75M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 3.89M | 2.84M | 2.97M | 8.54M | 7.68M |
| Inventory | 0 | 2.98M | 200K | 0 | 0 |
| Other Current Assets | 3.04M | 2.17M | 6.33M | (1K) | 2K |
| Total Current Assets | 93.06M | 52.36M | 87.34M | 61.47M | 62.75M |
| Property, Plant & Equipment (Net) | 8.19M | 7.12M | 6.11M | 5.54M | 4.57M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 4K | 1K | 8K | 7K | 10K |
| Long-term Investments | 98K | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 421K | 291K | 443K | 406K | 434K |
| Total Non-current Assets | 8.71M | 7.41M | 6.56M | 5.95M | 5.01M |
| Total Assets | 101.77M | 59.77M | 93.9M | 67.42M | 67.76M |
| Account Payables | 5M | 4M | 6.7M | 4.48M | 6.58M |
| Short-term Debt | 7.08M | 3.6M | 3.82M | 3.66M | 3.1M |
| Tax Payables | 5.08M | 6.6M | 7.38M | 6.87M | 6.82M |
| Deferred Revenue | 16.77M | 16.57M | 18.23M | 18.16M | 36.22M |
| Other Current Liabilities | 5.39M | 7.41M | 760K | 8.27M | 430K |
| Total Current Liabilities | 36.85M | 37.94M | 49.87M | 58.94M | 57.51M |
| Long-term Debt | 32.42M | 44.04M | 41.66M | 43.01M | 89.12M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 318K | 270K | 325K | 28.21M | 3.73M |
| Total Non-current Liabilities | 38.13M | 48.88M | 45.87M | 74.19M | 94.74M |
| Total Liabilities | 74.98M | 86.81M | 95.74M | 133.12M | 152.24M |
| Common Stock | 1.05M | 1.05M | 1.41M | 1.42M | 1.45M |
| Retained Earnings | (47M) | (57.04M) | (39.7M) | (68.13M) | (23.96M) |
| Accumulated OCI | (182.82M) | (226.58M) | (276.07M) | (311.51M) | (376.15M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 26.79M | (27.05M) | (1.84M) | (65.7M) | (84.48M) |
| Total Debt | 46.02M | 53.17M | 50.57M | 50.9M | 95.32M |
| Net Debt | (37.9M) | 11.78M | (24.72M) | 1.17M | 42.57M |
Nanobiotix S.A.
NASDAQ:NBTX
Intrinsic Alpha fair value
Locked
Current Price
$26.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.